Related references
Note: Only part of the references are listed.Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer
Xiaoyan Dou et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Simona Serrati et al.
MOLECULAR CANCER (2022)
Prognostic biomarkers of cutaneous melanoma
Liang Ding et al.
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE (2022)
Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma
Hangzhi Wei et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)
Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker
Kenneth Emancipator
AAPS JOURNAL (2021)
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
Marzia Del Re et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis
Yang Cheng et al.
FUTURE ONCOLOGY (2021)
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
Alberto Pavan et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Julianne D. Twomey et al.
AAPS JOURNAL (2021)
Exosome-based liquid biopsies in cancer: opportunities and challenges
W. Yu et al.
ANNALS OF ONCOLOGY (2021)
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Denis L. Jardim et al.
CANCER CELL (2021)
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
Allan Relecom et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
Yeon Jeong Kim et al.
SCIENTIFIC REPORTS (2021)
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
So Yeon Oh et al.
SCIENTIFIC REPORTS (2021)
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Filippo G. Dall'Olio et al.
CLINICAL LUNG CANCER (2021)
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
Ryotaro Ohkuma et al.
BIOMEDICINES (2021)
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
Biagio Ricciuti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
Alice Indini et al.
CANCERS (2021)
Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle
Elien Augustus et al.
CANCERS (2021)
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
Christian Sordo-Bahamonde et al.
CANCERS (2021)
Intra-Tumoral Genomic Heterogeneity in Rectal Cancer: Mutational Status Is Dependent on Preoperative Biopsy Depth and Location
Floris A. Vuijk et al.
CANCERS (2021)
The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
Luigi Fattore et al.
FRONTIERS IN ONCOLOGY (2021)
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2021)
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Heather A. Wakelee et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Thomas Powles et al.
NATURE (2021)
Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
Jialiang Yang et al.
FRONTIERS IN ONCOLOGY (2021)
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
Wei Zou et al.
JCO PRECISION ONCOLOGY (2021)
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
Jeffrey C. Thompson et al.
JCO PRECISION ONCOLOGY (2021)
Update of early phase clinical trials in cancer immunotherapy
Dae Ho Lee
BMB REPORTS (2021)
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy
Elena Maria Brozos-Vazquez et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
A. Passaro et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy
Selena Y. Lin et al.
CLINICAL CHEMISTRY (2020)
Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade
Miriam Moeller et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
Samuel J. Klempner et al.
ONCOLOGIST (2020)
TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer
Jiefei Han et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
Albrecht Stenzinger et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer
Maria A. Papadaki et al.
CANCERS (2020)
Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
Alex Friedlaender et al.
FRONTIERS IN ONCOLOGY (2020)
Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Aviad Ben-Shmuel et al.
FRONTIERS IN IMMUNOLOGY (2020)
KEAP1/NFE2L2 as a prognostic biomarker on immunotherapy and correlation with immune infiltrates in non-small cell lung cancer (NSCLC).
Hongyuan Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer.
Fahmin Basher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer
Yong-Hee Cho et al.
TARGETED ONCOLOGY (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice
Jernej Gaspersic et al.
BIOCHEMIA MEDICA (2020)
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Xue Bai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
Ye Li et al.
FRONTIERS IN ONCOLOGY (2020)
Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
Dantong Sun et al.
MOLECULAR MEDICINE (2020)
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Barzin Y. Nabet et al.
CELL (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
Marina Chiara Garassino et al.
LUNG CANCER (2020)
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials
Carmen Criscitiello et al.
ONCOLOGIST (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
Genetic and environmental determinants of human TCR repertoire diversity
Chirag Krishna et al.
IMMUNITY & AGEING (2020)
Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
Shumin Li et al.
FRONTIERS IN IMMUNOLOGY (2020)
Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer
Elisa Gobbini et al.
CANCERS (2020)
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy
Matthen Mathew et al.
CANCERS (2020)
Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma
Hiroe Tada et al.
SCIENTIFIC REPORTS (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
Linda Quatrini et al.
CANCERS (2020)
Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges
Kohei Yamashita et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2020)
PD-1-positive Natural Killer Cells have a weaker antitumor function than that of PD-1-negative Natural Killer Cells in Lung Cancer
Chao Niu et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2020)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
Derek L. Clouthier et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Assessment of tumor mutation burden calculation from gene panel sequencing data
Zhenwu Xu et al.
ONCOTARGETS AND THERAPY (2019)
Use of Circulating Tumor DNA for Cancer Immunotherapy
Alexandra Snyder et al.
CLINICAL CANCER RESEARCH (2019)
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study
Andrea Forschner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Melanie Janning et al.
CANCERS (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy
Yuting Liu et al.
CLINICAL CANCER RESEARCH (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer
Nicolas Guibert et al.
LUNG CANCER (2019)
The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer
Hye Ryun Kim et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
Mifanwy Reece et al.
FRONTIERS IN GENETICS (2019)
The circulating pool of functionally competent NK and CD8+cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
Giulia Mazzaschi et al.
LUNG CANCER (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Sabrina A. Hogan et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
Shu Lian et al.
SCIENTIFIC REPORTS (2019)
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Yoshiyuki Nakamura
FRONTIERS IN MEDICINE (2019)
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Laura Keller et al.
NATURE REVIEWS CANCER (2019)
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair et al.
FRONTIERS IN IMMUNOLOGY (2019)
Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer
Yoshikane Yamauchi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
Nicolas Guibert et al.
LUNG CANCER (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
Karim Boudadi et al.
Oncotarget (2018)
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
Chunyan Yue et al.
ONCOIMMUNOLOGY (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress
Martin H. D. Neumann et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
Dedong Cao et al.
ONCOIMMUNOLOGY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy
Francesca Fenizia et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Marie-Nicole Theodoraki et al.
CLINICAL CANCER RESEARCH (2018)
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab
Rajiv Raja et al.
CLINICAL CANCER RESEARCH (2018)
Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations
Francesc Castro-Giner et al.
DIAGNOSTICS (2018)
CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer
H. Zhang et al.
ONCOGENE (2017)
Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer
Mao Lin et al.
IMMUNOLOGY LETTERS (2017)
Circulating tumor cells: clinical validity and utility
Luc Cabel et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
Andrew Sharabi et al.
ONCOLOGIST (2017)
Proliferation of PD-1+CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients
Alice O. Kamphorst et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich
CANCER IMMUNOLOGY RESEARCH (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Janice M. Mehnert et al.
CLINICAL CANCER RESEARCH (2017)
Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study
Zilin Qin et al.
CANCER BIOLOGY & THERAPY (2017)
Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?
L. Cabel et al.
EJSO (2017)
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
J. H. Lee et al.
ANNALS OF ONCOLOGY (2017)
International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant
Alexandra S. Whale et al.
ANALYTICAL CHEMISTRY (2017)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Michael A. Postow et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Lidia Robert et al.
CLINICAL CANCER RESEARCH (2014)
New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use
Therese M. Becker et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Age-Related Decrease in TCR Repertoire Diversity Measured with Deep and Normalized Sequence Profiling
Olga V. Britanova et al.
JOURNAL OF IMMUNOLOGY (2014)
Diversity and clonal selection in the human T-cell repertoire
Qian Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Harnessing the exosome-induced immune response for cancer immunotherapy
Ulf Gehrmann et al.
SEMINARS IN CANCER BIOLOGY (2014)
Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes)
Theresa L. Whiteside
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma
Sojun Hoshimoto et al.
ANNALS OF SURGERY (2012)
Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells
Daniel Ramskold et al.
NATURE BIOTECHNOLOGY (2012)
Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody
Fuliang Chu et al.
BLOOD (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Share Paper
